Yazen achieved record-breaking growth in 2025, doubling its revenue.
In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.
Yazen doubles revenue and continues expansion in Europe
2025 marked another record-breaking year for the digital healthcare provider Yazen. Revenue increased from approximately €15.7 million to nearly €29.4 million – a growth of 87 percent. At the same time, gross profit doubled to around €16.5 million.
Yazen ended the year with over 37,000 active patients, and more than 53,000 patients have been treated since its inception. Collectively, patients have lost 643 tonnes in weight – a clear indication that Yazen’s combination of modern medications and lifestyle changes delivers effective, sustainable results.
Throughout the year, the company increased investments in growth, particularly in marketing. Total marketing and media investments exceeded €17.8 million. The EBITDA result was –€5.7 million, reflecting the company’s continued commitment to becoming Europe’s leading obesity treatment provider.
Rapid growth in Europe – Now present in seven countries
“We continue our expansion in Europe and now have a presence in seven markets. We are seeing strong growth in several of these and plan to establish ourselves in two additional countries during 2026,” says Fredrik Meurling, CEO of Yazen.
Strong development in the care team and service
Yazen now has a total of 290 employees (180 FTE), of which 220 are in the medical team. This includes 130 licensed physicians. As of January 2026, 39,000 patients were in active treatment.
The company’s recurring revenue (ARR) amounted to SEK 372 million at year-end.
International recognition
Yazen was named “Weight Loss Treatment of the Year in Europe 2025” by the international magazine Healthcare Business Review, and was also ranked as the second fastest growing startup in Europe according to The Sifted 250 Leaderboard.
